Ibiglustat

SKU: orb1302829

Description

Ibiglustat

Research Area

Metabolism Research

Key Properties

• CAS Number: 1401090-53-6
• MW: 389.49
• Purity: 98.24%
• Formula: C₂₀H₂₄FN₃O₂S
• SMILES: CC(C)(NC(=O)O[C@@H]1CN2CCC1CC2)c1csc(n1)-c1ccc(F)cc1
• Target: Transferase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.13 mM);DMSO:50 mg/mL (128.37 mM)

Bioactivity

• In Vitro:
  Ibiglustat is in phase II Clinical trials fo the treatment of Fabry's disease. Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations o the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy.

Storage & Handling

• Storage: store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Fabry disease, GZ402671, GZ-402671, GZ 402671, GL-3 levels, glucosylceramide synthase, Inhibitor, Ibiglustat, GBA, mutations, inhibit, oral, Parkinson's disease, SAR 402671, SAR402671, SAR-402671, Venglustat

Compound Identifiers

PubChem CID

60199242